Decitabine
- Generic Name
- Decitabine
- Brand Names
- Dacogen, Inqovi 5 Tablet Pack
- Drug Type
- Small Molecule
- Chemical Formula
- C8H12N4O4
- CAS Number
- 2353-33-5
- Unique Ingredient Identifier
- 776B62CQ27
- Background
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of cancerous cells can eventually lead to secondary acute myeloid leukemia, which has a poor prognosis. Among treatment option...
- Indication
Decitabine is indicated for the treatment of patients with myelodysplastic syndromes (MDS) including all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia), as well as for MDS scored ...
- Associated Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Associated Therapies
- -
Tegavivint for the Treatment of Relapsed or Refractory Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT04874480
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2022-08-30
- Target Recruit Count
- 3
- Registration Number
- NCT04854889
- Locations
- 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT04655391
- Locations
- 🇺🇸
City of Hope Meidcal Center, Duarte, California, United States
Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04553393
- Locations
- 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2020-11-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04493099
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 222
- Registration Number
- NCT04485052
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 33
- Registration Number
- NCT04482621
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia
- First Posted Date
- 2020-04-20
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 29
- Registration Number
- NCT04353479
Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
- Conditions
- Interventions
- First Posted Date
- 2020-04-07
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04337606
- Locations
- 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors
- First Posted Date
- 2020-03-03
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Li Yu
- Target Recruit Count
- 200
- Registration Number
- NCT04292769
- Locations
- 🇨🇳
Shenzhen university general hospital, Shenzhen, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.